People with depression are significantly more likely to develop Alzheimer’s disease. Our researchers seek to understand why.
The purpose of this study is to find out if reducing depressive symptoms with an antidepressant also improves levels of proteins associated with increased risk for developing Alzheimer’s disease (AD). The study will target individuals 60 and older with major depressive disorder. It will compare the FDA-approved SSRI antidepressant escitalopram with a placebo.
This research will contribute to knowledge about potentially modifiable risks for the prevention of AD in depressed individuals, who are at especially increased risk for this disease. Help researchers in this field and join our research study today!